HS
AXSM icon

HighVista Strategies’s Axsome Therapeutics AXSM Stock Holding History

HighVista Strategies’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.94M Sell
20,183
-254
-1% -$55.1K 1.13% 27
2026
Q1 		$3.45M Buy
20,437
+9,306
+84% +$1.61M 0.95% 32
2025
Q4 		$2.03M Buy
11,131
+1,783
+19% +$249K 0.52% 51
2025
Q3 		$1.14M Sell
9,348
-1,561
-14% -$176K 0.28% 113
2025
Q2 		$1.14M Sell
10,909
-10,594
-49% -$1.12M 0.42% 101
2025
Q1 		$2.51M Buy
21,503
+4,379
+26% +$499K 0.97% 19
2024
Q4 		$1.45M Sell
17,124
-24,418
-59% -$2.25M 0.54% 74
2024
Q3 		$3.73M Sell
41,542
-20,650
-33% -$1.8M 1.29% 17
2024
Q2 		$5.01M Buy
62,192
+13,665
+28% +$1.01M 1.83% 5
2024
Q1 		$3.87M Sell
48,527
-13,736
-22% -$1.15M 1.38% 17
2023
Q4 		$4.96M Buy
62,263
+5,299
+9% +$354K 1.8% 5
2023
Q3 		$3.98M Buy
56,964
+7,564
+15% +$565K 1.84% 10
2023
Q2 		$3.55M Sell
49,400
-11,374
-19% -$839K 1.62% 12
2023
Q1 		$3.75M Buy
60,774
+5,650
+10% +$371K 3.05% 4
2022
Q4 		$4.25M Buy
55,124
+38,238
+226% +$2.29M 2.52% 6
2022
Q3 		$753K Buy
+16,886
New +$844K 0.43% 63
2021
Q2 		– Sell
-11,664
Closed -$660K – 124
2021
Q1 		$660K Buy
11,664
+651
+6% +$45.8K 0.49% 47
2020
Q4 		$897K Buy
11,013
+5,001
+83% +$374K 0.57% 36
2020
Q3 		$428K Sell
6,012
-929
-13% -$72.4K 0.31% 63
2020
Q2 		$571K Buy
+6,941
New +$534K 0.47% 15

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HighVista Strategies's AXSM Position: Q2 2026 in Review

HighVista Strategies reduced its Axsome Therapeutics (AXSM) stake by 1.2% in Q2 2026, selling an estimated $55.1K and leaving 20,183 shares worth $4.94M. The position accounts for 1.13% of the portfolio, ranked #27.

HighVista Strategies first reported a position in AXSM in Q2 2020 and has held it in 20 quarters since. The position peaked at $5.01M in Q2 2024. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • HighVista Strategies held 20,183 shares of Axsome Therapeutics worth $4.94M as of Q2 2026.
  • HighVista Strategies sold 254 Axsome Therapeutics shares in Q2 2026, an estimated $55.1K.
  • Axsome Therapeutics made up 1.13% of HighVista Strategies's portfolio in Q2 2026, its #27 holding.
  • HighVista Strategies first reported a position in Axsome Therapeutics in Q2 2020 and has held it in 20 quarters since.
  • HighVista Strategies's Axsome Therapeutics position peaked at $5.01M in Q2 2024.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.